Genzyme Corporation

Geltex Pharmaceuticals, Inc.

Sanofi

Polaroid Corporation

Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

Pradeep K Dhal

Nino Meyer

Gary J Nabel

Lionel Vedrine

Stephen Randall Holmes-Farley

Chad Cori Huval

John S Petersen

Clark Qun Pan

Huawei Qiu

James E Stefano

Diego A Gianolio

Bo Chen

Robert J Miller

W Harry Mandeville, Iii

Xinhua Li

Qun Zhou

Dieter Kadereit

Michael Wagner

David J Harris

Andreas Evers

Martin Bossart

Thomas Olpp

Richard A Minns

Eric S Kolb

Torsten Haack

Susan Mancini Cady

Katrin Lorenz

David A Waldman

Thomas X Neenan

Richard T Ingwall

Richard Fitzpatrick

Mark Robson Humphries

Steven C Polomoscanik

Vitaly Nivorozhkin

Bruce Shutts

Paul Konowicz

Kanwen Yang

Peyman Sakhaii

Magnus Besev

Chih-Jen Wei

Izabela Galeska

Kurt Swanson

Guillaume Rigaut

Parag G Mehta

Howard G Schild

Peter D McDonnell

Craig Harvey Nelson

Nils Poth

S Randall Holmes-Farley

Michael Glenn Horner

Jeffrey D Klinger

Robert Miller

Alexis Guy André Lucien Parisot

Chinyere Agbugba

Celine Loss-Dunod

Carys Eleri Lee

Philip Just Larsen

Thomas Huebschle

Harry W Mandeville, Iii

Thorsten Schmidt

Ian Davison

Philip J Goddard

Ram Dharanipragada

Christina Laskar

Nicholas Oliver Harding

Stephen Randall Holms-Farley

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Site-specific antibody-drug conjugation through glycoengineering

Antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV are provided. Also provided are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.

Antigenic respiratory syncytial virus polypeptides

Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Hyperglycosylated binding polypeptides

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L-L-L-L-Y&#x2014;Rgroups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L-L-L-Y&#x2014;R, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist. 

Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y&#x2014;R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), 

Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative-containing multi-dose formulations. The preservative-containing multi-dose formulations exhibit resistance to one or more contaminating microorganisms, and have advantageous properties with respect to long term stability of biological and small molecule active ingredients.

Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative

The present invention relates to veterinary compositions and methods of treating and/or preventing mastitis in non-human mammals. More particularly, the present invention relates to the treatment of mastitis in cows. The veterinary composition comprises a water soluble, locally-acting, antimicrobial amine functional polyamide polymer.

Antimicrobial polyamide compositions and mastitis treatment

Amine functional polyamides comprise amine and ammonium groups along the polymer chain. Amine functional polyamides can be used as pharmaceutical agents and in pharmaceutical compositions. The amine functional polyamides are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis, surgical site infection, and lung infection associated with cystic fibrosis.

Amine functional polyamides

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Growing community of inventors

Westford, MA, United States of America

Pradeep K Dhal